Jun Wang

Quick facts

Marketed products

• intravenous hydromorphone
• intravenous hydromorphone and dexmedetomidine
• intravenous sufentanil
• intravenous sufentanil and dexmedetomidine

Phase 1 pipeline

• Human Interleukin-11

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jun Wang portfolio CI brief
• Jun Wang pipeline updates RSS